Oral propranolol combined with topical betaxolol for 8 children with high-risk infantile hemangiomas involving periocular region

doi:10.19438/j.cjoms.2020.03.015

Abstract

Abstract: PURPOSE: To assess the efficacy and safety of oral propranolol combined with betaxolol for high-risk infantile hemangiomas involving periocular region. METHODS: From August 2014 to January 2019 in 8 pediatric patients with high-risk hemangiomas, propranolol was administered orally at a daily dose of 0.5-2 mg/kg, betaxolol was applied to the tumor surface for ten minutes twice a day. The treatment lasted for half to one year or until a full recovery was achieved. The efficiency and safety of this treatment was assessed based on the changes of size, thickness, color, local peak systolic velocity before and after treatment and side effects during the therapy. SPSS 23.0 software package was used for statistical analysis. RESELTS: The mean treatment duration was 9.4 months and the mean score of efficacy was 77 points of 8 patients. The clinical response were evaluated as four patients for grade Ⅳ and another four for grade Ⅲ. No severe complications were observed. CONCLUSIONS: Oral propranolol combined with topical betaxolol is an effective and safe treatment for high-risk infantile hemangiomas involving periocular region.

Key words: Infantile hemangiomas, Propranolol, Betaxolol, Periocular region

CLC Number:

R739.8

LI Hong, ZHOU Yu-chuan, GONG Zhong-cheng, SUN Yang, LING Bin. Oral propranolol combined with topical betaxolol for 8 children with high-risk infantile hemangiomas involving periocular region[J]. China Journal of Oral and Maxillofacial Surgery, 2020, 18(3): 264-268.

References

[1] Léauté-Labrèze C, Harper JI, Hoeger PH.Infantile haemangioma[J]. Lancet, 2017, 390(10089): 85-94.
[2] Adams DM, Ricci KW.Infantile hemangiomas in the head and neck region[J]. Otolaryngol Clin North Am, 2018, 51(1): 77-87.
[3] Hutchinson AK, Kraker RT, Pineles SL, et al.The use of β-blockers for the treatment of periocular hemangiomas in infants[J]. Ophthalmology, 2019, 126(1): 146-155.
[4] 周昱川, 凌彬, 尹小朋, 等. 外涂盐酸倍他洛尔滴眼液治疗7例表浅型婴幼儿血管瘤疗效观察[J]. 中国口腔颌面外科杂志, 2017, 15(5): 438-441.
[5] 中华医学会整形外科分会血管瘤和脉管畸形学组. 血管瘤和脉管畸形的诊断及治疗指南(2019版)[J]. 组织工程与重建外科杂志, 2019, 15(5): 277-317.
[6] 郑家伟, 王绪凯, 秦中平, 等. 口服普萘洛尔治疗婴幼儿血管瘤中国专家共识[J]. 上海口腔医学, 2016, 25(3): 257-260.
[7] 凌彬, 刘洁, 张静, 等. 缺氧诱导因子1α在普萘洛尔治疗婴幼儿血管瘤患者中的表达与意义[J]. 口腔医学研究, 2014, 30(7): 659-662.
[8] Achauer BM, Chang CJ, Vander Cam VM.Management of hemangioma of infancy: review of 245 patients[J]. Plast Reconstr Surg, 1997, 99(5): 1301-1308.
[9] Haggstrom AN, Baselga E, Chamlin SL, et al.Localized infantile hemangiomas of the face and scalp: Predilection for the midline and periorbital and perioral skin[J]. Pediatr Dermatol, 2018, 35(6): 774-779.
[10] Zhao J, Huang AH, Rainer BM, et al.Periocular infantile hemangiomas: Characteristics, ocular sequelae, and outcomes[J]. Pediatr Dermatol, 2019, 36(6): 830-834.
[11] Samuelov L, Kinori M, Rychlik K, et al.Risk factors for ocular complications in periocular infantile hemangiomas[J]. Pediatr Dermatol, 2018, 35(4): 458-462.
[12] 邓佳欣, 陈悦, 陈媛, 等. 口腔颌面部血管瘤治疗的研究进展[J]. 口腔疾病防治, 2019, 27(1): 57-62.
[13] 宫贺, 徐大朋, 李越霄, 等. 0.5%马来酸噻吗洛尔滴眼液联合普萘洛尔治疗婴幼儿血管瘤疗效分析[J]. 中国口腔颌面外科杂志, 2014, 12(5): 441-445.
[14] Solman L, Glover M, Beattie PE, et al.Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology consensus guidelines[J]. Br J Dermatol, 2018, 179(3): 582-589.
[15] Krowchuk DP, Frieden IJ, Mancini AJ, et al.Clinical practice guideline for the management of infantile hemangiomas[J]. Pediatrics, 2019, 143(1): e20183475.
[16] Hagen R, Ghareeb E, Jalali O, et al.Infantile hemangiomas: what have we learned from propranolol?[J]. Curr Opin Pediatr, 2018, 30(4): 499-504.
[17] 诸骏仁, 桑国卫. 中华人民共和国药典临床用药须知: 化学药和生物制品卷(2005年版) [M]. 北京: 人民卫生出版社, 2005: 181-184.
[18] Chantasart D, Hao J, Li SK.Evaluation of skin Permeation of β-blockers for topical drug delivery[J]. Pharm Res, 2013, 30(3): 866-877.
[19] Zhang Q, Chantasart D, Li SK.Evaluation of blocker gel and effect of dosing volume for topical delivery[J]. J Pharm Sci, 2015, 104(5): 1721-1731.
[20] 武会芝, 李勇, 王霞, 等. β受体阻滞药治疗婴幼儿血管瘤作用机制的研究进展[J]. 中国药房, 2016, 27(8): 1143-1146.